Bemcentinib is a first-in-class Axl-specific small molecule kinase inhibitor that is in clinical trials for a variety of cancer indications, including melanoma (24), so its effects on tumor cell-macrophage interactions are clinically relevant. This evidence concerns the gene AXL and neoplasm.